News
GCVRZ
0.8711
0.00%
0.0000
Regeneron/ Sanofi say FDA has delayed Dupixent COPD label
Seeking Alpha · 05/31 10:49
Third human bird flu case found in U.S.
Seeking Alpha · 05/30 17:46
Moderna nearing deal to win U.S. funding for bird flu vaccine trial: FT
Seeking Alpha · 05/30 11:04
Evercore says biotech ‘winter is finally thawing’
Seeking Alpha · 05/14 15:24
Novavax’s sudden rise burns short sellers: report
Seeking Alpha · 05/11 11:59
AI-discovered drugs have an 80%–90% success rate: study
Seeking Alpha · 05/10 18:13
Novavax Ditches 'Going Concern,' Embraces Sanofi Safety Net (Rating Upgrade)
Seeking Alpha · 05/10 17:50
Novavax hits a 52-week high as Sanofi deal prompts J.P. Morgan upgrade
Seeking Alpha · 05/10 15:15
Novavax surges as Sanofi COVID vaccine deal boosts outlook
Seeking Alpha · 05/10 10:59
Regeneron falls after Q1 miss; announces $3B share buybacks
Seeking Alpha · 05/02 11:55
Sanofi Q1: Wait And See For Now (Downgrade)
Seeking Alpha · 05/01 18:27
Sanofi: Q1 Earnings Reflect Growth And Strategic Acquisitions (Rating Upgrade)
Seeking Alpha · 04/30 15:30
Sanofi Non-GAAP EPS of €1.78, revenue of €10.46B; reaffirms FY24 business EPS guidance
Seeking Alpha · 04/25 05:38
Sanofi succeeds in late-stage trial for blood disorder candidate
Seeking Alpha · 04/23 13:44
GLP-1s benefit Parkinson’s: Barclays sees implications across biopharma
Seeking Alpha · 04/12 16:02
Nurix gains after extending Sanofi research pact
Seeking Alpha · 04/09 18:15
CureVac posts early efficacy results for GSK-partnered flu shot
Seeking Alpha · 04/04 12:20
U.S. CDC warns bacteria causing meningitis are on the rise
Seeking Alpha · 03/30 14:50
FDA experts recommend changes to flu shots
Seeking Alpha · 03/07 18:29
Apogee Therapeutics' Innovative Leap In Atopic Dermatitis Management
Seeking Alpha · 03/05 18:28
More
Webull provides a variety of real-time GCVRZ stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About GCVRZ
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.